EcoDrugPlus

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSDORG00000013517
Gene Symbol: HTR1E
3 Cross references
157 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSDORG00000009973
Gene Symbol: HTR1F
4 Cross references
146 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSDORG00000029019
Gene Symbol: HTR2A
4 Cross references
217 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSDORG00000015361
Gene Symbol: HTR2B
4 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSDORG00000015746
Gene Symbol: HTR2C
4 Cross references
227 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSDORG00000014030
Gene Symbol: HTR3A
3 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSDORG00000014039
Gene Symbol: HTR3B
4 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSDORG00000014112
Gene Symbol: HTR5A
4 Cross references
216 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSDORG00000007540
Gene Symbol: HTR6
4 Cross references
115 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSDORG00000002925
Gene Symbol: HTR7
3 Cross references
221 Possible Orthologues:

60s Ribosomal Protein L17-Like

Ensembl ID : ENSDORG00000026216
Gene Symbol: LOC105987658
2 Cross references
325 Possible Orthologues:

60s Ribosomal Protein L39

Ensembl ID : ENSDORG00000026269
Gene Symbol: LOC105997471
3 Cross references
79 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).